Literature DB >> 25036269

Selection of potential predictors of worsening heart failure: rational and design of the SELENE HF study.

Luigi Padeletti1, Giovanni Luca Botto, Antonio Curnis, Ermenegildo De Ruvo, Antonio D'Onofrio, Edoardo Gronda, Renato Pietro Ricci, Antonello Vado, Gabriele Zanotto, Massimo Zecchin, Xenia Antoniou, Alessio Gargaro.   

Abstract

BACKGROUND: Heart failure is a leading cause of hospitalization and a significant medical burden in our society. Implantable medical devices are nowadays established therapies in heart failure patients that not only provide cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICDs) therapy but are also able to continuously and remotely monitor diagnostic information of various physiologic parameters. The value of combining individual diagnostic variables to predict worsening of heart failure is still largely unclear but could eventually become a valuable tool towards a better heart failure management.
METHODS: SELENE HF (Selection of potential predictors of worsening Heart Failure) is an observational, multicentre study designed to prospectively collect follow-up and home monitoring data trends from a population of individuals with ICDs with or without resynchronization therapy (CRT-D), to document heart failure hospitalizations and deaths and to correlate these events with Home Monitoring data in order to identify the combination with the greatest sensitivity and specificity in predicting heart failure events.The purpose of this study is to describe the design of the study focusing on the Heart Failure Predicting model and statistical approach that will be used to analyse the data.
CONCLUSION: The results of the SELENE HF study could help to select and define potential predictors of worsening heart failure in patients with remotely monitored ICD or CRT-D devices. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01836510.

Entities:  

Mesh:

Year:  2015        PMID: 25036269     DOI: 10.2459/JCM.0000000000000171

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  4 in total

1.  The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.).

Authors:  Andrea Di Lenarda; Giancarlo Casolo; Michele Massimo Gulizia; Nadia Aspromonte; Simonetta Scalvini; Andrea Mortara; Gianfranco Alunni; Renato Pietro Ricci; Roberto Mantovan; Giancarmine Russo; Gian Franco Gensini; Francesco Romeo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 2.  Remote monitoring: Doomed to let down or an attractive promise?

Authors:  Fabiana Lucà; Laura Cipolletta; Stefania Angela Di Fusco; Annamaria Iorio; Andrea Pozzi; Carmelo Massimiliano Rao; Nadia Ingianni; Manuela Benvenuto; Andrea Madeo; Damiana Fiscella; Daniela Benedetto; Giuseppina Maura Francese; Sandro Gelsomino; Massimo Zecchin; Domenico Gabrielli; Michele Massimo Gulizia
Journal:  Int J Cardiol Heart Vasc       Date:  2019-05-30

3.  Remote monitoring for heart failure management during COVID-19 pandemic.

Authors:  Enrico Bertagnin; Antonio Greco; Giuseppe Bottaro; Paolo Zappulla; Imma Romanazzi; Maria Daniela Russo; Marco Lo Presti; Noemi Valenti; Giuseppe Sollano; Valeria Calvi
Journal:  Int J Cardiol Heart Vasc       Date:  2021-01-28

4.  Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.

Authors:  Antonio D'Onofrio; Francesco Solimene; Leonardo Calò; Valeria Calvi; Miguel Viscusi; Donato Melissano; Vitantonio Russo; Antonio Rapacciuolo; Andrea Campana; Fabrizio Caravati; Paolo Bonfanti; Gabriele Zanotto; Edoardo Gronda; Antonello Vado; Vittorio Calzolari; Giovanni Luca Botto; Massimo Zecchin; Luca Bontempi; Daniele Giacopelli; Alessio Gargaro; Luigi Padeletti
Journal:  Europace       Date:  2022-02-02       Impact factor: 5.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.